



BD, ten23 health, and partners to demo full RFID syringe traceability at CPHI Frankfurt

New collaboration brings hands-on tour of unit-level traceability in injectable drug manufacturing to CPHI 2025

Frankfurt, Germany – October 15, 2025: ten23 health, the human-centric and sustainable strategic CDMO partner of choice for the pharmaceutical industry and biotech start-ups, BD (Becton, Dickinson and Company), together with Harro Höfliger and Crypto Pharma will jointly present an end-to-end demonstration of RFID-enabled syringe traceability at CPHI 2025, running October 28–30 in Frankfurt. The BD iDFill™ RFID Integration Tour will allow registered attendees to experience a full production cycle – from filling to final device assembly – across four booths, highlighting how unit-level identification can improve safety, quality, and compliance in injectable drug production.

“We are excited about the experience provided to CPHI attendees. Our partnership with BD, Harro Höfliger and Crypto Pharma demonstrates the possibilities that RFID technology can offer and also shows that ten23 is at the forefront of innovation,” said Hanns-Christian Mahler, CEO of ten23 health.

Fernand Goldblat, VP/GM BD Medical-Pharmaceutical Systems, Prefillable Syringes Platform commented: *“The BD iDFill™ RFID Integration Tour at CPHI Frankfurt provides a unique, hands-on experience to observe the full workflow in action from filling to final assembly. It demonstrates how RFID-enabled prefillable syringes are now part of the existing ecosystem supporting efficiency, deviation management, and compliance.”*


“Manufacturers need greater efficiency, regulators demand enhanced traceability, and patients deserve certainty in product integrity. The CPHI demonstration shows how industry collaboration transforms unit-level traceability from concept to reality,” added Thomas Hiltbrand, CEO and Founder, Crypto Pharma.

The BD iDFill™ RFID Integration Tour is open to all CPHI 2025 attendees, with two small-group sessions per day (8–12 participants per tour, ~60 minutes). Visitors will move between four partner booths to follow an RFID-enabled syringe through key manufacturing steps: filling (Bausch + Ströbel), inspection (Körper), assembly (Harro Höfliger), and packaging with full unit-level data capture (ten23 health).

The collaboration builds on growing demand for digital traceability in pharma, driven by stricter regulatory expectations and the need for faster deviation management.

Experience end-to-end traceability in action with BD iFill™ Individual Prefillable Syringe Identification*

A unique, hands-on experience to observe the full BD iFill™ workflow in action from filling to final assembly



- BD uses RFID chips in the syringe lids (BD iFill™) to ensure syringe traceability throughout every step of the filling process.
- ten23 health is a CDMO that develops, manufactures, and tests sterile medicines for the pharmaceutical industry and biotech start-ups.
- Harro Höflinger enables lab-scale assembly of injection devices using its semi-automatic Assembly Lab, supporting approval-phase manufacturing.
- Crypto Pharma increases manufacturing efficiency and ensures product integrity through innovative unit-level traceability solutions.

Link for a registration: [BD iFill Tour RFID Integration Tour – CPHI 2025](#)

About ten23 health

ten23 health®, located in Basel and Visp, Switzerland, is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: we develop, manufacture, and test modern medicines. We support our clients in developing differentiated, stable, usable, and safe injectable treatment options for patients.

ten23 health® combines the latest scientific findings with proven and tested world-class industry and regulatory expertise to forge new paths for supporting clients. We provide our innovative services in a fair and sustainable manner, respecting people's health and the future of our planet. ten23 health® is a B Corp member and solidly financed through the long-term commitment of 3i Group, an internationally reputable equity partner.

[ten23 health – your human-centric and sustainable CDMO](#)

About the company's name

The numeric value for the number of molecules in a sample of one mol is called Avogadro constant and equals $6.022 \cdot 10^{23}$. Gram quantities of material contain the incredible number of 10^{23} atoms, which was an important discovery to understand the composition of matter: The world is built from small units, and not a homogeneous mass.



About 3i Group

3i is an investment company with two complementary businesses, Private Equity and Infrastructure, and invests in mid-market companies headquartered in Europe and North America. 3i's Private Equity team provides investment solutions for growing companies, backing entrepreneurs and management teams of companies with an EV typically between €100m - €500m. 3i backs international growth plans, providing access to its network and expertise to accelerate the growth of companies across the consumer, healthcare, industrial and private label, and services and software industries.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on [LinkedIn](#), X (formerly Twitter) [@BDandCo](#) or Instagram [@becton_dickinson](#).

About Crypto Pharma

Crypto Pharma Solutions AG (Basel, Switzerland) provides RFID-based unit-level traceability solutions for pharmaceutical manufacturing. The company's platform eliminates manual reconciliation, prevents mix-ups, enables precise batch segregation and dissolves data silos through seamless integration with filling machines and inspection systems. Validated through multiple pilot studies, Crypto Pharma develops interoperable solutions through strategic partnerships across the pharmaceutical value chain—from primary packaging manufacturers to fill-finish operations, device assembly and secondary packaging.

Contacts:

ten23 health: Marija Petrovic, marija.petrovic@ten23.health;

3i Group: Kathryn van der Kroft, Kathryn.VanDerKroft@3i.com;

BD: Troy Kirkpatrick, VP, Public Relations; troy.kirkpatrick@bd.com;

BD: Adam Reiffe, Sr. Director, Investor Relations; adam.reiffe@bd.com;

Crypto Pharma: Thomas Hiltbrand, CEO and Founder; thomas.hiltbrand@crypto-pharma.ch

